This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  


Orbit Discovery and Evergreen Theragnostics expand research collaboration to advance targeted therapeutics development

Orbit Discovery, a leading provider of peptide discovery services, and Evergreen Theragnostics, a radiopharmaceutical company at the forefront of precision medicine, have announced an extension to their research collaboration to find novel targeting peptides for radiopharmaceutical delivery. This collaboration expands upon a previous agreement signed between the companies in April 2023 whereby technology synergies have enabled the... Read more

EIT and University of Oxford join forces in a transformative strategic alliance with an investment of £130m

University of Oxford and the Ellison Institute of Technology (EIT) announced today that they are entering a long-term strategic alliance to develop the solutions and future leaders needed to tackle some of the greatest and most enduring challenges facing humanity. This will involve an overall investment of £130m from EIT. The alliance was confirmed in a signing ceremony which took place at Oxford's Clarendon Building. The University of... Read more

EVENT: Imaging Membrane Proteins in Real Time

Come along to an event hosted by Sitryx to hear expert insights from The Kennedy Insitute of Rheumatology and The Rosalind Franklin Institute. Read more

Theolytics doses first patient in trial to treat ovarian cancer

Theolytics, a clinical-stage biotechnology company developing next-generation oncolytic immunotherapies, has dosed the first patient in its Phase I/IIa multi-centre, open-label first-in-human trial (OCTOPOD - NCT06618235) of THEO-260 in patients with advanced-stage platinum-resistant ovarian cancer (PROC). Ovarian Cancer is one of the leading causes of cancer related deaths among women. It exhibits a stromal rich, immune-suppressed TME,... Read more

EIT Oxford at The Oxford Science Park

We recently spoke to Lisa Flashner, COO of EIT Oxford, about why a leading medical research and development centre in California chose The Oxford Science Park as the location for its European campus. Proximity to the world’s leading university and world-class research institutions; access to great minds and scientific discovery; a thriving, collaborative innovation community; and the availability of high-spec laboratory space are all reasons... Read more

The Daubeny Project

Imaginative design, inspiring spaces.